A little over a year after cutting 21% of its workforce, Spruce Biosciences has disclosed it’s axing 55% of its employees, according to an April 25 SEC filing. The San Francisco–based late-stage biopharma had 21 employees as of Dec. 31, 2024, according to an April 15 SEC filing, meaning that the layoffs could leave the business with around 10 employees.
